Vnitr Lek 2005, 51(2):221-225

Adiponectin - the new adipocyte-derived hormone with relation to obesity and insulin resistance

J. Housová1,*, D. Housa2, M. Haluzík1
1 III. interní klinika 1. lékařské fakulty UK a VFN, Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
2 Ústav patologie 3. lékařské fakulty UK a FN Královské Vinohrady, Praha, přednosta prof. MUDr. Václav Mandys, CSc.

It is generally accepted that adipose tissue is an endocrine organ producing number of hormones. These hormones play an important role in the food intake regulation and significantly affect the development of atherosclerosis and insulin resistance respectively. Adiponectin - a recently discovered adipocyte-derived hormone - is one of the most extensively studied adipocytokines. There is a growing number of both experimental and clinical evidence suggesting that adiponectin is an important ethiopathogenic factor in the development of insulin resistance, diabetes and atherosclerosis. The aim of this article is to review the current state of knowledge concerning the regulation of adiponectin production and its relationship to above mentioned diseases. The possible therapeutic potential of this hormone in the treatment of insulin resistance and/or atherosclerosis will be also discused.

Keywords: adiponectin; diabetes mellitus; insulin resistance

Received: February 10, 2004; Accepted: April 20, 2004; Published: February 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Housová J, Housa D, Haluzík M. Adiponectin - the new adipocyte-derived hormone with relation to obesity and insulin resistance. Vnitr Lek. 2005;51(2):221-225.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372(6505): 425-432. Go to original source... Go to PubMed...
    2. Halaas JL, Gajiwala KS, Maffei M et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995; 269(5223): 543-546. Go to original source... Go to PubMed...
    3. Hube F, Hauner H. The role of TNF-alpha in human adipose tissue: prevention of weight gain at the expense of insulin resistance? Horm Metab Res 1999; 31(12): 626-631. Go to original source... Go to PubMed...
    4. Juhan-Vague I, Renucci JF, Grimaux M et al. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2000; 20(9): 2156-2161. Go to original source... Go to PubMed...
    5. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409(6818): 307-312. Go to original source... Go to PubMed...
    6. Scherer PE, Williams S, Fogliano M et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270(45): 26746-26749. Go to original source... Go to PubMed...
    7. Maeda K, Okubo K, Shimomura I et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996; 221(2): 286-289. Go to original source... Go to PubMed...
    8. Nakano Y, Tobe T, Choi-Miura NH et al. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) 1996; 120(4): 803-812. Go to original source... Go to PubMed...
    9. Viengchareun S, Zennaro MC, Pascual-Le Tallec L et al. Brown adipocytes are novel sites of expression and regulation of adiponectin and resistin. FEBS Lett 2002; 532(3): 345-350. Go to original source... Go to PubMed...
    10. Pajvani UB, Du X, Combs TP et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 2003; 278(11): 9073-9085. Go to original source... Go to PubMed...
    11. Tsao TS, Murrey HE, Hug C et al. Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J Biol Chem 2002; 277(33): 29359-29362. Go to original source... Go to PubMed...
    12. Tsao TS, Tomas E, Murrey HE et al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J Biol Chem 2003; 278(50): 50810-50817. Go to original source... Go to PubMed...
    13. Kobayashi H, Ouchi N, Kihara S et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004; 94(4): 27-31. Go to original source... Go to PubMed...
    14. Combs TP, Pajvani UB, Berg AH et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 2004; 145(1): 367-383. Go to original source... Go to PubMed...
    15. Yamauchi T, Kamon J, Ito Y et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423(6941): 762-769. Go to original source... Go to PubMed...
    16. Arita Y, Kihara S, Ouchi N et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002; 105(24): 2893-2898. Go to original source... Go to PubMed...
    17. Hotta K, Funahashi T, Bodkin NL et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001; 50(5): 1126-1133. Go to original source... Go to PubMed...
    18. Yang WS, Lee WJ, Funahashi T et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86(8): 3815-3819. Go to original source... Go to PubMed...
    19. Fasshauer M, Klein J, Neumann S et al. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002; 290(3): 1084-1089. Go to original source... Go to PubMed...
    20. Makimura H, Mizuno TM, Bergen H et al. Adiponectin is stimulated by adrenalectomy in ob/ob mice and is highly correlated with resistin mRNA. Am J Physiol Endocrinol Metab 2002; 283(6): E1266-E1271. Go to original source... Go to PubMed...
    21. Berg AH, Combs TP, Du X et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7(8): 947-953. Go to original source... Go to PubMed...
    22. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86(5): 1930-1935. Go to original source... Go to PubMed...
    23. Delporte ML, Funahashi T, Takahashi M et al. Pre- and post-translational negative effect of beta-adrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies. Biochem J 2002; 367(3): 677-685. Go to original source... Go to PubMed...
    24. Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20(6): 1595-1599. Go to original source... Go to PubMed...
    25. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7(8): 941-946. Go to original source... Go to PubMed...
    26. Haluzik M, Colombo C, Gavrilova O et al. Genetic background (C57BL/6J versus FVB/N) strongly influences the severity of diabetes and insulin resistance in ob/ob mice. Diabetes 2003; 52(Suppl 1): A328-A328. Go to original source...
    27. Fruebis J, Tsao TS, Javorschi S et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98(4): 2005-2010. Go to original source...
    28. Wang Y, Xu A, Knight C et al. Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. J Biol Chem 2002; 277(22): 19521-19529. Go to original source... Go to PubMed...
    29. Colombo C, Cutson JJ, Yamauchi T et al. Transplantation of adipose tissue lacking leptin is unable to reverse the metabolic abnormalities associated with lipoatrophy. Diabetes 2002; 51(9): 2727-2733. Go to original source... Go to PubMed...
    30. Combs TP, Berg AH, Obici S et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001; 108(12): 1875-1881. Go to original source... Go to PubMed...
    31. Maeda N, Shimomura I, Kishida K et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8(7): 731-737. Go to original source... Go to PubMed...
    32. Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 277(29): 25863-25866. Go to original source... Go to PubMed...
    33. Ma K, Cabrero A, Saha PK et al. Increased beta-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem 2002; 277(38): 34658-34661. Go to original source... Go to PubMed...
    34. Combs TP, Wagner JA, Berger J et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 2002; 143(3): 998-1007. Go to original source... Go to PubMed...
    35. Maeda N, Takahashi M, Funahashi T et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50(9): 2094-2099. Go to original source... Go to PubMed...
    36. Yu JG, Javorschi S, Hevener AL et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002; 51(10): 2968-2974. Go to original source... Go to PubMed...
    37. Abbasi F, Lamendola C, McLaughlin T et al. Plasma adiponectin concentrations do not increase in association with moderate weight loss in insulin-resistant, obese women. Metabolism 2004; 53(3): 280-283. Go to original source... Go to PubMed...
    38. Stefan N, Bunt JC, Salbe AD et al. Plasma adiponectin concentrations in children: relationships with obesity and insulinemia. J Clin Endocrinol Metab 2002; 87(10): 4652-4656. Go to original source... Go to PubMed...
    39. Ouchi N, Kihara S, Arita Y et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103(8): 1057-1063. Go to original source... Go to PubMed...
    40. Yamauchi T, Kamon J, Waki H et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003; 278(4): 2461-2468. Go to original source... Go to PubMed...
    41. Okamoto Y, Kihara S, Ouchi N et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106(22): 2767-2770. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.